Erudio Healtherudio.com
Clinical trial · no report yet · Phase 4
GUARD-01
Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma
- NCT05723991 ↗
- Unknown
- Chunguang yang (101937)
- Focused
We haven't built an HCP commentary report on GUARD-01 (disitamab vedotin and gemcitabine in Radical Cystectomy) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on GUARD-01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Evaluation of an Open, Single Arm, Multicenter Phase II Clinical Study on the Neoadjuvant Treatment of HER2 Expressing Myometrial Invasive Bladder Cancer With Disitamab Vedotin for Injection and Gemcitabine
- Phase
- Phase 4
- Status
- Unknown
- Conditions
- Radical Cystectomy; Urothelial Carcinoma
- Interventions
- Disitamab Vedotin and Gemcitabine
- Arms
- Vidiximab and Gemcitabine Neoadjuvant therapy · Experimental
- Enrollment
- 36 (estimated)
- Primary outcomes
- Pathologic Complete Response
- Sponsor
- Chunguang yang (101937)
- Start
- Sep 28, 2022
- Primary completion
- Sep 28, 2024 (estimated)
- Results posted
- No
- Registry record
- NCT05723991 · updated Feb 13, 2023